Efficacy of immunotherapy in advanced gastric cancer: preliminary results of a multicenter observational study
Authors:
- A. B. RaysARA. B. Rays
- М. Yu. FedyaninМFМ. Yu. Fedyanin
- D. V. PopovDPD. V. Popov
- I. А. PokataevIPI. А. Pokataev
- М. A. LyadovaМLМ. A. Lyadova
- L. G. ZhukovaLZL. G. Zhukova
- D. L. StroyakovskyDSD. L. Stroyakovsky
- М. В. ВолконскийМВМ. В. Волконский
- D. А. GavrilovaDGD. А. Gavrilova
- N. S. BesovaNBN. S. Besova
- А. А. TryakinАTА. А. Tryakin
Open Access
- 24 May 2024
- journal article
- research article
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (2) , 9-18
Abstract
Background: Due to the low efficacy of PD-L1 antibodies in second and subsequent lines of metastatic gastric cancer (mGC), the optimal treatment strategy of such patients and appropriate choice of predictive biomarkers remain challenging. The aim of our study is to assess the efficacy of immune checkpoint inhibitors monotherapy in patients with mGC in routine clinical practice, especially in heavily-pretreated patients. Materials and methods: We retrospectively analyzed data of patients treated in five oncology centers in Moscow between 2018 and 2023, who received nivolumab or pembrolizumab for advanced gastric cancer. Primary end-point of our study was 6-months PFS. Secondary end-points were overall survival (OS), objective respons e rate (ORR), and disease control rate (DCR). Toxicity was assessed using CTC AE v5.0 scale. Results: 122 patients with mGC who received immune checkpoint inhibitors were included between 1 January 2018 and 28 February 2023. 6-months PFS rate was 31,6 %. The median OS was 7 months (95 % CI: 2–20), the median PFS was 3 months (95 % CI: 1,5–9,5). A statistically significant difference in OS was detected in patients with MSI compared to MSS (25 months vs 6 months; 95 % CI: 0,21–0,86; HR: 0,43). A trend towards higher PFS was observed as well (10 months in MSI vs 3 months in MSS; 95 % CI:0,26–1,01; HR: 0,51). No statistical significance in PFS and OS according to PD-L1 CPS was found among patients with MSS. ORR and DCR were 36,6 % and 10,6 %, respectively. No cases of pseudoprogression or fatal immune-related AEs were observed. Conclusion: Our real-world data is consistent with published literature and the results from clinical trials. Further studies are needed to determine prognostic factors and to establish prognostic model of patients receiving ICIs for optimal treatment strategy of mGC.Keywords
This publication has 23 references indexed in Scilit:
- FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIOEuropean Journal of Cancer, 2022
- Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08)Gastric Cancer, 2021
- Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS studyESMO Open, 2021
- Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical TrialsJAMA Oncology, 2021
- Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction CancerClinical Colorectal Cancer, 2020
- Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancerGastric Cancer, 2019
- Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approachesCellular and Molecular Life Sciences, 2018
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction CancerJAMA Oncology, 2018
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2017
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialThe Lancet Oncology, 2014